Roger McIntyre
Professor of Psychiatry and Pharmacology at the University of Toronto
Data updated
Research Footprint
Roger McIntyre appears in 34 tracked papers (2018–2026), most studied alongside Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Jonathan Rosenblat, Rodrigo Mansur and Shokouh Meshkat.
Publication Landscape
How the 34 papers Blossom tracks for Roger McIntyre line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Roger McIntyre's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 34 of 34 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Roger McIntyre publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Roger McIntyre publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Roger McIntyre is one of the world's most cited researchers in the field of depression and bipolar disorder. Head of the Mood Disorders Psychopharmacology Unit at UHN, he has been instrumental in the clinical implementation of ketamine for treatment-resistant depression. He leads multiple international initiatives to improve brain health and psychiatric care through innovative pharmacological and psychedelic research.
Key Impact
A global leader in mood disorder research and a pioneer in rapid-acting treatments like ketamine.
Collaboration Network
41 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Roger McIntyre's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Roger McIntyre is associated with.
University of Toronto Mississauga
academicThe Psychedelic Studies Research Program (PSRP) distinguishes itself by adhering strictly to the principles of Open Science, pre-registering their analysis plans, and making their data and protocols freely accessible. A primary focus for the team at the PSRP is the clinical study of microdosing. Led by Dr. Norman Farb, the program conducts double-blind, randomized controlled trials investigating the benefits and drawbacks of microdosing very low doses of psilocybin.
View stakeholder →Braxia Scientific Corp.
Public BiotechBraxia Scientific Corp. (CSE: BRAX) is a Canadian publicly-listed medical research company that operates a network of ketamine and psilocybin treatment clinics across Ontario and Quebec through its subsidiary Canadian Rapid Treatment Centre of Excellence, and conducted Canada's first multi-dose Phase II psilocybin randomized controlled trial for treatment-resistant depression. The company received Health Canada Special Access Program approval to deliver psilocybin-assisted therapy in Ontario and holds government-funded grants for ketamine trials in bipolar depression, led by researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →